About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a company based in Boston (United States) founded in 1996 was acquired by Paratek Pharma in July 2014. Transcept Pharmaceuticals has raised $40 million across 2 funding rounds from investors including Hercules Capital, Paratek Pharma and New Leaf Venture Partners. Transcept Pharmaceuticals has completed 1 acquisition, including Novacea. Transcept Pharmaceuticals operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Boston, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Transcept Pharmaceuticals, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$40 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series D
Mar 01, 2007
-
Investors
Hercules Capital
& 8 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Paratek Pharma
(Jul 01, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Transcept Pharmaceuticals
Transcept Pharmaceuticals has successfully raised a total of $40M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $40 million completed in March 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Transcept Pharmaceuticals
Transcept Pharmaceuticals has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include Hercules Capital, Paratek Pharma and New Leaf Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked |
Investor details for Transcept Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Transcept Pharmaceuticals
Transcept Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Novacea.
Investment portfolio details for Transcept Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Serotonin inhibitor drugs for cancer are developed by Novacea.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Transcept Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Transcept Pharmaceuticals
Detailed financials for Transcept Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Transcept Pharmaceuticals Comparisons
Peer comparison for Transcept Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Transcept Pharmaceuticals
Transcept Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| Locked | Locked | Locked |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| Locked | Locked | Locked |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
Detailed competitors of Transcept Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Transcept Pharmaceuticals
Complete news archive for Transcept Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transcept Pharmaceuticals
Transcept Pharmaceuticals was founded in 1996 and raised its 1st funding round 5 years after it was founded.
Transcept Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Transcept Pharmaceuticals is a funded company, having raised a total of $40M across 2 funding rounds to date.
Paratek is focused on the discovery, development, and commercialization of medicines that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Lead product candidate, omadacycline (phase 3), is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections. It is also developing sacrecycline (phase 3) for acne in partnership with Allergan. Other pipeline compounds include 2 molecules in phase 3 for acquired bacterial pneumonia infections and skin structure infections.
Transcept Pharmaceuticals's top competitors include Insmed, MaaT Pharma and Basilea.
Transcept Pharmaceuticals has made 1 acquisition, including Novacea.
Transcept Pharmaceuticals has 9 investors. Key investors include Hercules Capital, Paratek Pharma, New Leaf Venture Partners, NEA, and InterWest.